Short-Term Outcome of Infliximab Therapy in Pediatric Crohn's Disease: A Single-Center Experience

Overview

Journal Pediatr Gastroenterol Hepatol Nutr

Date 2018 Jan 6

PMID 29302505

Citations 1

Authors

Dai Jung

Sunghee Lee

Insook Jeong

Seak Hee Oh

Kyung Mo Kim

Affiliations

Soon will be listed here.

Abstract

Purpose: Studies on the efficacy of infliximab (IFX) in a large population of pediatric patients with Crohn's disease (CD) are limited, and prognostic factors are not well-known. The aim of this study was to evaluate outcomes of IFX in pediatric patients with CD and to identify factors associated with poor prognosis.

Methods: We retrospectively analyzed medical data of 594 pediatric patients with CD between 1987 and 2013 in a tertiary center. Of these, 156 children treated with IFX were enrolled and were followed up for at least a year with intact data. Outcomes of induction and maintenance, classified as failure or clinical response, were evaluated on the tenth and 54th week of IFX therapy.

Results: We treated 156 pediatric patients with CD with IFX, and the median duration of IFX therapy was 47 months. For IFX induction therapy, 134 (85.9%) patients experienced clinical response on the 10th week. Among the 134 patients who showed response to induction, 111 (82.8%) patients maintained the clinical response on the 54th week. In multivariate analysis, low hematocrit (=0.046) at the time of IFX initiation was associated with the failure of IFX induction. For IFX maintenance therapy, longer duration from the initial diagnosis to IFX therapy (=0.017) was associated with maintenance failure on the 54th week.

Conclusion: We have shown the acceptable outcomes of IFX in a large cohort of pediatric CD patients in Korea. Hematocrit and early introduction of IFX may be prognostic factors for the outcomes of IFX.

Citing Articles

Mucosal Immunity Related to FOXP3 Regulatory T Cells, Th17 Cells and Cytokines in Pediatric Inflammatory Bowel Disease.

Cho J, Kim S, Yang D, Lee J, Park K, Go J J Korean Med Sci. 2018; 33(52):e336.

PMID: 30584414 PMC: 6300656. DOI: 10.3346/jkms.2018.33.e336.

References

Grossi V, Lerer T, Griffiths A, LeLeiko N, Cabrera J, Otley A . Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease. Clin Gastroenterol Hepatol. 2015; 13(10):1748-56. DOI: 10.1016/j.cgh.2015.04.010. View

. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria. J Pediatr Gastroenterol Nutr. 2005; 41(1):1-7. DOI: 10.1097/01.mpg.0000163736.30261.82. View

Hyams J, Markowitz J, Otley A, Rosh J, Mack D, Bousvaros A . Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr. 2005; 41(4):416-21. DOI: 10.1097/01.mpg.0000183350.46795.42. View

Kim B, Song S, Kim K, Lee Y, Rhee K, Jang J . Characteristics and trends in the incidence of inflammatory bowel disease in Korean children: a single-center experience. Dig Dis Sci. 2009; 55(7):1989-95. DOI: 10.1007/s10620-009-0963-5. View

Koutroubakis I, Ramos-Rivers C, Regueiro M, Koutroumpakis E, Click B, Schwartz M . The Influence of Anti-tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015; 21(7):1587-93. PMC: 4466024. DOI: 10.1097/MIB.0000000000000417. View

Ruffolo C, Scarpa M, Bassi N . Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 363(11):1086-7. DOI: 10.1056/NEJMc1005805. View

Koutroubakis I, Ramos-Rivers C, Regueiro M, Koutroumpakis E, Click B, Schoen R . Persistent or Recurrent Anemia Is Associated With Severe and Disabling Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2015; 13(10):1760-6. PMC: 4702483. DOI: 10.1016/j.cgh.2015.03.029. View

Nahon S, Lahmek P, Paupard T, Lesgourgues B, Chaussade S, Peyrin-Biroulet L . Diagnostic Delay Is Associated with a Greater Risk of Early Surgery in a French Cohort of Crohn's Disease Patients. Dig Dis Sci. 2016; 61(11):3278-3284. DOI: 10.1007/s10620-016-4189-z. View

Park J, Yang S, Ye B, Kim J, Park D, Yoon H . Second Korean guidelines for the management of Crohn's disease. Intest Res. 2017; 15(1):38-67. PMC: 5323307. DOI: 10.5217/ir.2017.15.1.38. View

10.

Lee Y, Kang B, Lee Y, Kim M, Choe Y . Infliximab "Top-Down" Strategy is Superior to "Step-Up" in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr. 2015; 60(6):737-43. DOI: 10.1097/MPG.0000000000000711. View

11.

Vahabnezhad E, Rabizadeh S, Dubinsky M . A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2014; 20(4):606-13. PMC: 5330671. DOI: 10.1097/MIB.0000000000000003. View

12.

Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J . Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007; 132(3):863-73. DOI: 10.1053/j.gastro.2006.12.003. View

13.

Best W, Becktel J, SINGLETON J, KERN Jr F . Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70(3):439-44. View

14.

deBruyn J, Jacobson K, El-Matary W, Carroll M, Wine E, Wrobel I . Long-term Outcomes of Infliximab Use for Pediatric Crohn Disease: A Canadian Multicenter Clinical Practice Experience. J Pediatr Gastroenterol Nutr. 2017; 66(2):268-273. DOI: 10.1097/MPG.0000000000001672. View

15.

Church P, Guan J, Walters T, Frost K, Assa A, Muise A . Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease. Inflamm Bowel Dis. 2014; 20(7):1177-86. DOI: 10.1097/MIB.0000000000000083. View

16.

Walters T, Kim M, Denson L, Griffiths A, Dubinsky M, Markowitz J . Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease. Gastroenterology. 2013; 146(2):383-91. DOI: 10.1053/j.gastro.2013.10.027. View

17.

Levine A, Griffiths A, Markowitz J, Wilson D, Turner D, Russell R . Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011; 17(6):1314-21. DOI: 10.1002/ibd.21493. View

18.

Ma C, Beilman C, Huang V, Fedorak D, Kroeker K, Dieleman L . Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study. Inflamm Bowel Dis. 2016; 22(4):870-9. DOI: 10.1097/MIB.0000000000000679. View

19.

Hyams J, Ferry G, Mandel F, GRYBOSKI J, Kibort P, Kirschner B . Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991; 12(4):439-47. View

20.

Ruemmele F, Veres G, Kolho K, Griffiths A, Levine A, Escher J . Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014; 8(10):1179-207. DOI: 10.1016/j.crohns.2014.04.005. View